lisuride has been researched along with cabergoline in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Audinot, V; Boutin, JA; Cussac, D; Maiofiss, L; Millan, MJ; Newman-Tancredi, A | 1 |
| Bhatt, MH; Calne, DB; Fleetham, JA; Keenan, SP | 1 |
| Riva di Sanseverino, L; Sabatino, P; Tonani, R | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Gekht, AB | 1 |
| Calda, P; Pavlista, D; Zivný, J | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Bernard, N; Descotes, J; Gillet, A; Gouraud, A; Mirkou, A; Suchovsky, D; Vial, T | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R | 1 |
6 review(s) available for lisuride and cabergoline
| Article | Year |
|---|---|
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone | 2002 |
[Use of dopamine agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors | 2002 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2 | 2021 |
1 trial(s) available for lisuride and cabergoline
| Article | Year |
|---|---|
[Arrest of lactation after 2nd trimester abortion with a single dose of cabergoline in comparison with 10-day administration of teguride].
Topics: Abortion, Induced; Adolescent; Adult; Cabergoline; Drug Administration Schedule; Ergolines; Female; Humans; Lactation; Lisuride; Pregnancy; Pregnancy Trimester, Second; Prospective Studies | 2003 |
4 other study(ies) available for lisuride and cabergoline
| Article | Year |
|---|---|
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Topics: Animals; Antiparkinson Agents; Binding Sites; Binding, Competitive; Cholinergic Antagonists; Cloning, Molecular; Cluster Analysis; Dopamine Agonists; Humans; Rats; Receptor, Muscarinic M1; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Histamine H1; Receptors, Muscarinic; Receptors, Neurotransmitter; Receptors, Serotonin | 2002 |
Pleuropulmonary disease associated with dopamine agonist therapy.
Topics: Aged; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Lisuride; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Diseases; Radiography | 1991 |
X-ray crystal structure and conformational analysis of N-(3-dimethylaminopropyl)-N-(ethylaminocarbonyl)-6-(2-propenyl)er goline -8 beta-carboxamide (Cabergoline): comparison with bromocriptine and lisuride and a hypothesis for its high dopaminergic activi
Topics: Bromocriptine; Cabergoline; Crystallography, X-Ray; Dopamine Agonists; Ergolines; Lisuride; Molecular Conformation; Structure-Activity Relationship | 1995 |
[Prescription of ergot derivatives for lactation inhibition in France: Current practices].
Topics: Bromocriptine; Cabergoline; Dihydroergocryptine; Dopamine Agonists; Ergolines; Ergot Alkaloids; Female; France; Humans; Lactation; Lisuride; Practice Patterns, Physicians'; Prolactin; Surveys and Questionnaires | 2012 |